Literature DB >> 35559383

Biodistribution of mesenchymal stem cells (MSCs) in animal models and implied role of exosomes following systemic delivery of MSCs: a systematic review.

Alvin Man Lung Chan1, Yashirdisai Sampasivam2, Yogeswaran Lokanathan1.   

Abstract

Mesenchymal stem cells (MSC) are promising candidates to combat the growing rates of chronic degenerative diseases. These cells provide regeneration and/or differentiation into other cell types, and secrete various trophic factors that participate in migration, proliferation, and immunomodulation. However, the novelty of MSC research has noticeably declined as common barriers and unresolved challenges prevent further progress. A common issue is the low survivability and migration of systemically infused MSC towards targeted regions. Nevertheless, successful clinical treatment of various chronic diseases suggests that the MSCs may have an alternative mechanism. Recent advancements have shown labelling and imaging techniques to be a reliable source of data. These data not only illustrate the biodistribution but can be referenced to either support and/or improve the specificities of the cellular therapy construct. In this review, we compile recent studies between 2017 and 2021 to determine the homing and migration of MSCs by specific and peripherally-targeted organs. We also compare the different cell-tracking assays with the safety and efficacy of their therapeutic construct. We found that the common route of MSCs occurred in the lungs, liver, kidney and spleen. Furthermore, MSCs were also able to home and migrate towards targeted or injured organs such as the heart and lymph nodes. Although the MSCs were not detectable by the end of the study, the tested animals had significantly improved in terms of the disease symptoms and their related comorbidities. Thus, we hypothesize that the secretion of exosomes had contributed to this phenomenon. AJTR
Copyright © 2022.

Entities:  

Keywords:  Mesenchymal stem/stromal cells; biodistribution; cell tracking; imaging; in vivo; pharmacokinetics

Year:  2022        PMID: 35559383      PMCID: PMC9091132     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  60 in total

1.  Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy.

Authors:  Dario Furlani; Murat Ugurlucan; LeeLee Ong; Karen Bieback; Erik Pittermann; Ingeborg Westien; Weiwei Wang; Can Yerebakan; Wenzhong Li; Ralf Gaebel; Ren-ke Li; Brigitte Vollmar; Gustav Steinhoff; Nan Ma
Journal:  Microvasc Res       Date:  2009-02-26       Impact factor: 3.514

2.  Tandem Delivery of Multiple Therapeutic Genes Using Umbilical Cord Blood Cells Improves Symptomatic Outcomes in ALS.

Authors:  Rustem Robertovich Islamov; Albert Anatolyevich Rizvanov; Valeria Yuryevna Fedotova; Andrey Alexandrovich Izmailov; Zufar Zufarovich Safiullov; Ekaterina Evgenyevna Garanina; Ilnur Ildusovich Salafutdinov; Mikhail Evgenyevich Sokolov; Marat Alexandrovich Mukhamedyarov; András Palotás
Journal:  Mol Neurobiol       Date:  2016-08-06       Impact factor: 5.590

3.  Mesenchymal Stromal Cells Modulate Peripheral Stress-Induced Innate Immune Activation Indirectly Limiting the Emergence of Neuroinflammation-Driven Depressive and Anxiety-like Behaviors.

Authors:  Denis Gallagher; Fyyaz Siddiqui; Joseph Fish; Maxwell Charlat; Emaan Chaudry; Siddiq Moolla; Andrée Gauthier-Fisher; Clifford Librach
Journal:  Biol Psychiatry       Date:  2019-07-29       Impact factor: 13.382

4.  Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion.

Authors:  E Eggenhofer; V Benseler; A Kroemer; F C Popp; E K Geissler; H J Schlitt; C C Baan; M H Dahlke; M J Hoogduijn
Journal:  Front Immunol       Date:  2012-09-26       Impact factor: 7.561

Review 5.  The roles of tumor-derived exosomes in cancer pathogenesis.

Authors:  Chenjie Yang; Paul D Robbins
Journal:  Clin Dev Immunol       Date:  2011-11-30

6.  Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy.

Authors:  Li Liao; Bingzheng Shi; Heran Chang; Xiaoxia Su; Lichao Zhang; Chunsheng Bi; Yi Shuai; Xiaoyan Du; Zhihong Deng; Yan Jin
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

7.  The Pros and Cons of Mesenchymal Stem Cell-Based Therapies.

Authors:  Aleksandra Musiał-Wysocka; Marta Kot; Marcin Majka
Journal:  Cell Transplant       Date:  2019-04-24       Impact factor: 4.064

Review 8.  Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation.

Authors:  Michela Salvadori; Nicola Cesari; Alba Murgia; Paola Puccini; Benedetta Riccardi; Massimo Dominici
Journal:  Mol Ther Methods Clin Dev       Date:  2019-05-17       Impact factor: 6.698

Review 9.  Biodistribution of mesenchymal stem/stromal cells in a preclinical setting.

Authors:  Luc Sensebé; Sandrine Fleury-Cappellesso
Journal:  Stem Cells Int       Date:  2013-10-10       Impact factor: 5.443

10.  Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor In Exosome-Mediated Cytotoxicity Against Tumor.

Authors:  Anna Laura Di Pace; Nicola Tumino; Francesca Besi; Claudia Alicata; Libenzio Adrian Conti; Enrico Munari; Enrico Maggi; Paola Vacca; Lorenzo Moretta
Journal:  Cancers (Basel)       Date:  2020-03-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.